Theriva Biologics (TOVX) risk factors

58 risks, 8 new, 1 dropped, 13 reworded since the prior year. The company faces going concern doubts with an accumulated deficit of $358.7 million, needing capital while using $16.7 million in operating cash.

51 risks. Theriva Biologics faces going concern warnings with $11.6 million in cash against $16.9 million in annual operating losses. The company relies heavily on clinical development of its lead oncolytic virus candidate VCN-01 for pancreatic cancer. Operations are vulnerable to third-party manufacturing dependencies, strict FDA and European regulations, and required future capital raises.